Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System
Funds a biologic for a nervous system disorder from lead optimisation to phase I, with NIH-paid manufacturing and tox work — and the applicant keeps the IP.
This is one of the most commercially unusual awards in the whole federal catalogue, and the reason is in its intellectual property terms.
What it funds is biologic-based therapeutic discovery and development for disorders of the nervous system, from lead optimisation through phase I clinical testing. The modalities named are wide: large biologic macromolecules such as proteins, antibodies and pep…
Preclinical discovery and development of biologic therapeutics for nervous system disorders — proteins, antibodies, peptides, oligonucleotide and viral gene therapies, cell therapies, and microbial and microbiome therapies — from lead optimisation through phase I, with access to programme-funded consultants and contract research organisations for manufacturing, scaling, pharmacokinetics, toxicology and phase I testing.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up